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Abstract
Rheumatoid arthritis (RA) and other rheumatic diseases are associated with a significant defect in the galactosyltransfer-
ase enzyme that results in a profound change in the galactosylation of immunoglobulin G. This change has been
demonstrated to be integrally associated with pathogenic mechanisms associated with inflammation in RA. It is not thought
that these changes are unique to RA, but it is thought that there may be subtle changes in the disruption of glycosylation
homeostasis causing a unique sugar change to be associated with a number of other rheumatic diseases. This is referred to as
‘sugar printing the rheumatic diseases’ and may be a concept useful both diagnostically and therapeutically. ß 1999
Elsevier Science B.V. All rights reserved.
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1. Introduction
Oligosaccharide biochemistry has been an impor-
tant ¢eld of research for many years and this area of
basic science continues to £ourish [1].
Glycobiology deals with the nature and role of
carbohydrates in biological events [2^4]. It is now
clear the oligosaccharides may indeed be more than
a decorative irrelevance when it comes to molecular
mechanisms of disease [5^12]. The last decade has
witnessed an exponential interest in the associations
of oligosaccharides with disease mechanisms, and
signi¢cant advances have been made in the design
of carbohydrate-based therapies and diagnostic tech-
niques.
2. Oligosaccharide synthesis
Recent work from many laboratories has high-
lighted the fact that oligosaccharides are mediators
of biospeci¢c information by virtue of their structur-
al complexity. For example, the sialyl-Lewisx tetra-
saccharide is one of the crucial molecules involved in
cell adhesion and tra⁄cking [4,13,14]. The mecha-
nisms of their synthesis are therefore crucial. At the
centre stage of the synthesis of glycoside bonds are
the glycosyltransferase whose speci¢city for their
substrates, the donor sugar nucleotides, and acceptor
is precise [15]. The catalytic function which the gly-
cosyltransferases exerts is usually reversible, but not
in the case of immunoglobulin G (IgG), and results
in generation of nucleotide diphosphates which are
degraded to monophosphates by phosphatases co-lo-
calised with glycosyltransferases. The nucleoside-
monophosphate is then exchanged by an antiport
mechanism across the Golgi membrane with newly
made sugar-nucleotides synthesised in the cytoplasm.
The most important organelle involved in glycosyl-
ation is the Golgi apparatus (GA) originally de-
scribed as ‘appareil reticulaire interne’ by Camillo
Golgi in 1898 and then con¢rmed to be a morpho-
logical entity by electron microscopy [16]. Its bio-
chemical properties have been explored by fractiona-
tion using galactosyltransferase (GTase) as a marker
enzyme. Immunoelectron microscopical localisation
of this and other enzymes has clearly established
the GA as the site of glycan chain elongation and
termination [17,18]. The enzyme function within the
cisterne is well ordered and GTase has been found
predominantly on the trans-side of the GA. Recent
work has indicated that there is a sequential arrange-
ment of the glycosyltransferases, which increases
their biosynthetic e⁄ciency [19]. The sequential ac-
tion of glycosyltransferases produces oligosaccharide
and glycan structures that re£ect the constitution of
the multi-glycosyltransferase system [20] of a given
cell type and implies that the targeting mechanism
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for glycosyltransferases along the secretory pathway
is highly ordered [21]. The synthesis of a glycan spe-
ci¢c for a given cell type thus depends on a variety of
factors [22], for example:
b the expression of functional glycosyltransferase at
the proper location within the cell ;
b synthesis and translocation of sugar nucleotides to
the biosynthetic micro-environmental of the Golgi
lumen;
b the proper tra⁄cking of intra-cellular acceptor
substrates;
b absence of toxic in£uences, such as inhibitors of
processing enzymes and glycosyltransferases.
3. Galactosyltransferase
The glycoprotein UDPL1,4 GTase is an intracellu-
lar membrane-bound enzyme that can be localised to
the Golgi apparatus [23], but may also be found on
the cell surface [24] and in a soluble form in milk,
amniotic £uid, cerebrospinal £uid, saliva, urine and
serum [25].
The molecular role of GTase is to catalyse the
transfer of galactose from UDP-galactose to an N-
acetylglucosamine (GlcNAc) acceptor during oligo-
saccharide elongation, for example, in IgG glycosyl-
ation [26]. The gene encoding human GTase is
thought to be located in chromosome 9 [27], and it
may specify more than one mRNA transcript [28].
GTase seems to play a multifunctional role in nor-
mal cell physiology and has been associated with
sperm^egg binding [29], cell^cell recognition [30], em-
bryonic maturation [31], and cell development [32].
4. Immunoglobulin G
The glycoprotein IgG has a conserved N-linked
glycosylation site in the Fc region, with variable gly-
cosylation in the Fab depending on the presence or
absence of the glycosylation motif in the variable
region and whether it is conformationally available
to be glycosylated. Investigation of the glycoforms of
serum IgG has established signi¢cant di¡erences in
oligosaccharide structure between groups of patients
with certain diseases compared with IgG from
healthy controls. Di¡erent glycoforms arise due to
the presence or absence of certain sugar residues on
the oligosaccharide backbone [33]. Fig. 1 shows a
composite structure of the N-linked oligosaccharide
chain on human IgG and indicates how some struc-
tural variations can arise.
5. Rheumatoid arthritis
Rheumatoid arthritis (RA) is a multisystem disor-
der in which immunological abnormalities character-
istically result in symmetrical joint in£ammation, ar-
ticular erosions and extra-articular complications. It
is the most common and disabling autoimmune ar-
thritis, and genetic susceptibility is well de¢ned [34].
6. Quanti¢cation of IgG sugars in RA
Several di¡erent chromatographic methods and a
lectin-based assay have been compared for the quan-
titation of oligosaccharides released from IgG (Fig.
2) [35]. The analysis of a series of IgG samples puri-
¢ed from the serum of rheumatoid arthritis (RA)
patients was carried out by these methods to evaluate
the percentage of the glycoforms having 0, 1 or 2
galactose residues (G0, G1 and G2). It was then
possible to: (a) identify the method that can be
most widely used for quantitation; (b) accurately de-
¢ne the range of G0 values found in patients with
RA; and (c) make available a series of characterised
standards for distribution to clinical chemistry labo-
ratories. Individual experiments were carried out us-
ing a variety of chromatographic methods, as fol-
lows: release of oligosaccharides by glycosamidase
A after protease digestion followed by HPLC analy-
sis of aminopyridine derivatives on reverse phase and
normal phase columns; hydrazinolysis treatment
with exoglycosidases (L-hexosaminidase and K-fuco-
sidase) and Biogel P4 chromatography of 2-amino-
benzamide (2-AB) derivatives; hydrazinolysis and
weak anion exchange or normal phase HPLC of 2-
AB derivatives; release of oligosaccharides by
PNGase F and either Biogel P4 chromatography of
2-AB derivatives or HPAEC-PAD analysis of native
oligosaccharides. Comparison of the G0 values given
by these individual methods compared favourably
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with each other and a dot blot assay of denatured
IgG interaction with Ricinus communis agglutinin and
Bandeiraea simplicifolia lectin II.
7. RA and pregnancy
7.1. Galactosylation of IgG
To examine the relevance of glycosylation changes
to the pathogenesis of RA, we have examined the
oligosaccharide composition of IgG in relation to
the amelioration of RA during pregnancy, which oc-
curs in 75% of RA patients [36].
Serum IgG levels of terminal GlcNAc, galactose
and K2,6-sialic acid were compared in a selected
group of pregnant RA patients (n = 23) with active
disease, that was comprised of 11 patients who
achieved spontaneous remission and 12 patients
that did not. The latter group was further sub-di-
vided into two groups depending on whether their
disease activity remained unchanged or relapsed.
Longitudinal lectin analysis revealed unique pat-
terns of IgG oligosaccharide variation in the three
groups examined. Although the observed microheter-
ogeneity involved both the terminal galactose as well
as the levels of exposed GlcNAc, the remission group
had a distinct pattern and was speci¢cally associated
with a signi¢cant decrease (P6 0.05) in mean IgG
GlcNAc levels. Overall, the temporal changes in ga-
lactose and GlcNAc and the time frame at which
they occurred were found to be critical discerning
factors associated with the clinical outcome of the
disease during pregnancy.
In addition, analysis of the inter-relationship be-
tween Gal and GlcNAc in individual IgG samples,
during the initial 13 weeks of gestation, demon-
strated further important di¡erences between the
three groups. There was a signi¢cant negative corre-
lation in the remission group, which was in direct
contrast to the positive correlation found for the re-
lapse IgG samples.
Correlation P-value
Remission 30.80 6 0.05
Unchanged 30.43 NS
Relapse +0.87 6 0.05
7.2. K3-Fucosylation of K1-acid glycoprotein
In all three categories, changes in the plasma level
and glycosylation of K1-acid glycoprotein (AGP)
were determined longitudinally in comparison to
those occurring in pregnancy of healthy women
(Fig. 3) [37]. In healthy pregnancy, we observed:
(1) a peak in the plasma concentration at week 18
and a minimum at week 30; (2) a continuous in-
crease in the degree of branching of the glycans dur-
ing the entire pregnancy period; and (3) a decrease in
Fig. 2. Summary of the di¡erent methods employed to study a
panel of IgG molecules of rheumatoid sera [35].
Fig. 1. A composite structure of the N-linked oligosaccharide
chain on human IgG. Common structural variations include
change in content of sialic acid, galactose and bisecting N-ace-
tylglucosamine [40].
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the degree of K3-fucosylation of AGP-glycans with a
minimum occurring at week 25. Comparable preg-
nancy-induced changes in glycosylation were found
for two other acute-phase proteins K1-protease inhib-
itor (P1) and K1-antichymotrypsin (ACT).
Increased oestrogen levels, known to occur during
pregnancy, may be one of the factors that induce
these changes, because the increased branching and
decreased K3-fucosylation are in agreement with ear-
lier ¢ndings regarding the involvement of this hor-
mone in the regulation of acute phase glycosylation
in oestrogen-treated males as well as females [38]. In
all three clinical categories in RA, pregnancy also
induced a continuous increase in the degree of
branching of the glycans of AGP. However, similar
changes in concentration and fucosylation were only
found during remission of the disease symptoms. In
the relapse and unchanged categories in RA, the de-
gree of fucosylation and the plasma concentration of
AGP remained constant throughout pregnancy. This
indicates a relationship between changes in K3-fuco-
sylation of AGP and RA disease activity.
Fig. 3. Reactivity of AGP (a,d), ACT (b,e) and PI (c,f) from healthy individuals (HSPC) with ConA to estimate branching (left panel)
and AAL to estimate fucosylation (right panel). Sera were subjected to CAIE. Only the second dimension gels are shown. The lower
right corner of each pattern corresponds to the site of application in the ¢rst dimension gel. Electrophoresis was performed from right
to left in the ¢rst dimensions, and from bottom to top for the second dimension, C0 and A0, glycoforms non-reactive with ConA or
AAL respectively; Cw and Aw, glycoforms weakly reactive with ConA and AAL, respectively; Cs and As, glycoforms strongly reac-
tive with ConA and AAL, respectively. No fractionation was obtained when samples were analysed in the absence of lectin, resulting
in recovery of all protein at the position of C0 or A0 [37].
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8. Agalactosyl-IgG and rheumatoid factor binding
We have used a series of IgG preparations di¡er-
ing in their content of oligosaccharide chains lacking
galactose (G0) from 18 to 86% to determine whether
changes in sugar content a¡ect the binding of rheu-
matoid factor [39]. Five of 16 monoclonal rheuma-
toid factors prepared from synovial tissue, from pa-
tients with juvenile or adult rheumatoid arthritis,
bound better to IgG, which was de¢cient in galactose
(Fig. 4). Six of the 16 rheumatoid factors from the
same patients bound independently of the galactose
content. Four of the 16 rheumatoid factors could not
be absolutely grouped in this manner, but seemed to
demonstrate a preference for agalactosyl-IgG. One
rheumatoid factor bound better to fully galacto-
sylated IgG. There was an association between en-
hanced binding to galactose-de¢cient IgG and
mono-reactivity, and a very strong association be-
tween the functional a⁄nity of the rheumatoid fac-
tors and the dependent binding.
9. Glycosylation homeostasis within RA lymphocytes
is abnormal
To investigate potential mechanisms controlling
protein glycosylation we have studied the inter-rela-
Fig. 4. Binding of ¢ve synovial tissue-derived IgM monoclonal
RFs to IgG preparations varying in G0. The horizontal axis
represents G0 and the vertical axis represents optical density at
450 nm wavelength. A line of best ¢t is shown for each graph
[39].
Fig. 5. B lymphocytic galactosyltransferase activity (mean cpm/
mg proteinU105 þ S.E.M.) in the total RA population and di-
vided according to drug therapy. Control, 35 þ 4; All RA,
21 þ 3; Gpl (NSAID or no drugs), 14 þ 5; Gp2 (SASP), 28 þ 8;
Gp.3 (other second/third line therapy), 21 þ 4. Bars de¢ne the
mean þ S.E.M. Signi¢cance of di¡erence from controls:
*P6 0.01; **P6 0.002; ***P6 0.05 [40].
Fig. 6. Regression analysis of control (closed diamonds and
broken line, r = 0.770, P6 0.001) and RA (open diamonds and
unbroken line, r = 0.691, P6 0.001) paired B and T lymphocytic
galactosyltransferase activities [40].
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tionship between lymphocytic GTase activity and se-
rum agalactosylated immunoglobulin G levels (G0)
in healthy individuals and patients with RA and non-
autoimmune arthritis [40]. In RA there was reduced
GTase activity (Fig. 5) and increased G0. A positive
linear correlation between B and T cell GTase was
found in all individuals (Fig. 6). There was a weak
relationship between GTase and G0 which was
found to be positive and linear in the control pop-
ulation (Fig. 7) and negative and linear in the RA
population (Fig. 8). These data describe a defect in
RA lymphocytic GTase, with associated abnormal
G0 changes. A possible regulatory mechanism con-
trolling galactosylation in normal cells is suggested.
This is disrupted in RA, where the positive feedback
between GTase and G0 is lost. We suggest that these
mechanisms are of relevance to the pathogenesis of
RA, and that their manipulation may form part of a
novel therapeutic approach.
10. Are the rheumatoid arthritis associated
glycosylation abnormalities unique?
We have investigated the relationship between ex-
posed galactose and GlcNAc on IgG in RA, juvenile
chronic arthritis (JCA) and Sjogren’s syndrome (SS)
[41]. This was achieved using IgG isolated from se-
rum where the levels of galactose and GlcNAc were
Fig. 7. Regression analysis of paired B (open triangles and un-
broken line) and T (closed triangles and dotted line) lympho-
cytic galactosyltransferase activities and serum agalacto-immu-
noglobulin G (percent serum IgG G0) in the control population
(r = 0.263 and 0.211 for B and T cells, respectively, P6 0.05)
[40].
Fig. 8. Regression analysis of paired B lymphocytic galactosyl-
transferase activity and serum agalacto-immunoglobulin G val-
ues (percent serum IgG G0) in the rheumatoid arthritis popula-
tion (r =30.338, P6 0.004). There is a signi¢cant di¡erence
(P6 0.01) when this value is compared with the control regres-
sion value (r = 0.263) [40].
Fig. 9. (a) Correlation between galactose and GlcNAc levels on
RA IgG (n = 29). (b) Correlation between galactose and
GlcNAc levels on JCA IgG (n = 11). (c) Correlation between
galactose and GlcNAc levels on SS IgG (n = 37). (d) Correla-
tion between galactose and GlcNAc levels on normal IgG
(n = 100) [41].
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detected using biotinylated lectins. Galactose and
GlcNAc on IgG from patients with RA and JCA
are inversely related, but in contrast, in SS, galactose
expression on IgG decreased while GlcNAc expres-
sion remained similar to normal levels (Fig. 9). Alter-
ations on IgG glycosylation are closely associated
with the development of RA, JCA and SS, but the
changes involved are di¡erent in RA compared with
SS, suggesting that the precise pattern of exposed
sugars is associated with di¡erent rheumatological
changes.
11. Sugar printing rheumatic disease is possible
To look for oligosaccharide structural variants of
IgG that may be unique to speci¢c rheumatic dis-
eases, normal phase high performance liquid chro-
matography (HPLC) (Fig. 10) technology was used
and a comparison made of the oligosaccharide pools
released from serum IgG from patients with systemic
lupus erythematosus (SLE) (n = 10), ankylosing spon-
dylitis (AS) (n = 10), primary Sjogren’s syndrome
(PSS) (n = 6), JCA (n = 13), PsA (n = 9), RA (n = 5)
and healthy individuals (n = 19) [42].
The oligosaccharide pools were resolved into 13
peaks and the relative proportions of the peaks in
each disease group were signi¢cantly di¡erent from
those in healthy controls (P6 0.001^0.05). A charac-
teristic serum IgG oligosaccharide pro¢le or sugar
print for each of the rheumatic diseases was found.
The sugar prints exhibited a range of glycosylation
patterns whereby all RA (P6 0.001) and JCA
(P6 0.006) patients had predominantly agalacto-
sylated structures, while SLE (P6 0.03^0.0001) and
AS (P6 0.025^0.0001) patients had predominantly
digalactosyl structures.
The data suggest that each disease is associated
with a speci¢c mechanism giving rise to alterations
in the normal glycosylation pattern of IgG. Sugar
printing of IgG is therefore a potential means for
the di¡erentiation of rheumatic diseases and may
provide insight into disease pathogenesis.
12. Rapid pro¢ling of IgG N-glycans by £uorophore-
coupled oligosaccharide electrophoresis has the
potential of di¡erentiating rheumatic diseases
A rapid cost-e¡ective test which discriminates be-
tween rheumatic diseases in their early stages is still
not available to the Rheumatologist. One clinical
feature of the rheumatic diseases, which may be ex-
ploited in the development of a diagnostic test, is the
change in the glycosylation pro¢le of IgG and IgG
sugar printing may be potentially useful in this re-
spect. However, a more rapid investigation than
HPLC analysis is required. To enable rapid pro¢ling
of IgG sugars, a £uorophore coupled oligosaccharide
electrophoresis (FCOE) system was developed to an-
alyse IgG oligosaccharides derived from patients
with rheumatic disease [43].
The glycans from patients with RA (n = 20), PsA
(n = 5), AS (n = 14), JCA (n = 9), SLE (n = 19) and
healthy controls (n = 10) were released by PNGase
F and labelled with 2-amino benzoic acid. They
were resolved on 30% polyacrylamide gels using
tris-glycine into nine bands.
Oligosaccharide pro¢les were obtained for each
group and comparison made between digalactosyl-
fucosylated (g2f) structures (Band 1) and agalacto-
syl-fucosylated (g0f) structures (Band 4). Signi¢cant
reduction (g2f) and elevation (g0f) in band intensity
were noted in RA (g2f and g0f P6 0.001), PsA (g0f,
P6 0.001) and JCA (g2f P6 0.002) compared to
healthy controls. RA was signi¢cantly di¡erent
Fig. 10. An example of a normal phase HPLC pro¢le from a
healthy control, annotated to show the oligosaccharide struc-
tures represented by each peak. Normal phase resolves 16 oligo-
saccharides into 13 peaks. There are four agalactosyl and four
digalactosl oligosaccharide peaks and monogalactosyl oligosac-
charides form ¢ve peaks with co-elution of di¡erent oligosac-
charides according to their arm speci¢city [42].
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from AS (g0f, P6 0.001), JCA (g0f, P6 0.001) and
SLE (g0f and g2f, P6 0.001).
These data would indicate that FCOE is a rapid
test that appears to have the potential of di¡erentiat-
ing rheumatic diseases.
13. In what way could GTase enzymatic control be
abnormal?
We have investigated possible speci¢c L1,4 GTase
isoenzyme changes in serum of patients with RA [44].
Using solution phase isoelectric focusing, we have
determined the isoenzyme pro¢les in GTase in
healthy individuals (n = 9) (Fig. 11) and patients
with PsA (n = 9) and RA (n = 8) (Fig. 12). GTase
activity was determined using a previously reported
assay, in which 3H-galactose is transferred to oval-
bumin.
Comparison of GTase isoenzyme activity pro¢les
demonstrated that the RA group (Fig. 12) was sig-
ni¢cantly di¡erent from both the PsA patients and
healthy individuals (Fig. 11) (P6 0.01). In seven pa-
tients with RA, eight healthy individuals and six with
psoriatic arthritis, two fractions showed distinct
peaks of activity. The ¢rst peak of activity formed
at pH 4.5 (range 4.3^4.7), pH 4.6 (range 4.4^5.0)
and 4.65 (range 4.35^5.0), whilst the second peak
of activity focused at pH 5.0 (range 5.0^5.1), pH
5.0^5.4 and 5.20 (range 5.0^5.50) in RA, healthy in-
dividuals and PsA populations, respectively. There
was a signi¢cant shift in the PI position of the second
peak when comparing the RA group to the healthy
individuals (P = 0.006). A signi¢cant increase in
GTase activity was noted in the RA second peak
(P = 0.008) when compared to healthy individuals
and PsA.
Two main peaks of serum GTase activity have
therefore been identi¢ed and there is thus evidence
that RA associated serum GTase isoenzymes occur.
The RA GTase isoenzyme pro¢le is signi¢cantly dif-
ferent from the healthy individuals and PsA as there
is acidic skewing of the ¢rst peak, a prominent sec-
ond peak concentrated over a narrow pH band (pH
4.97^5.11) and a loss of activity in the pH range
5.20^5.60. The signi¢cance of these ¢ndings now
needs to be determined with reference to RA patho-
genesis and the enzyme contained within these peaks
fully characterised.
Fig. 11. A pro¢le of GTase activity plotted against pH follow-
ing solution phase isoelectric focusing of serum from a healthy
individual. There is a large peak forming at pH 4.55 and a
much smaller peak at pH 5.20 [44].
Fig. 12. This is a pro¢le of GTase activity plotted against pH
following solution phase isoelectric focusing of serum from a
patient with RA. A large peak is seen at pH 4.65 and a smaller
peak forms at pH 5.05. There is a left shift of the second peak,
and it constitutes a signi¢cantly greater proportion of the total
activity when compared to the healthy population [44].
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14. Conclusion
To date, our work concerning the glycoimmunol-
ogy of RA and other rheumatic diseases has demon-
strated a signi¢cant defect in the GTase enzyme that
results in a profound change in the galactosylation of
IgG. This change has been demonstrated to be inte-
grally associated with pathogenic mechanisms asso-
ciated with in£ammation in RA. It is hypothesised
that there are major disruptions in glycosylation ho-
meostasis associated with the pathogenesis of RA
and that perhaps in part these involve the generation
of unique GTase isoenzymes that di¡er functionally
from those present in healthy individuals. It is not
thought that these changes are unique to RA, but it
is thought that there may be subtle changes in the
disruption of glycosylation homeostasis causing a
unique sugar change to be associated with a number
of other rheumatic diseases. This is referred to as
‘sugar printing the rheumatic diseases’ and may be
a concept both useful diagnostically and therapeuti-
cally.
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